Core Viewpoint - BioVie Inc. is hosting a virtual investor event to discuss the unmet needs and treatment landscape for long COVID, featuring KOL Lindsay McAlpine, MD, on April 10, 2025 [1] Group 1: Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, including long COVID, Alzheimer's disease, and Parkinson's disease [6] - The company's drug candidate, bezisterim (NE3107), is an oral, blood-brain barrier-permeable, anti-inflammatory agent that selectively inhibits inflammation-driven mediators without affecting their homeostatic functions [2][6] - BioVie is also developing BIV201, an orphan drug candidate for advanced liver disease, which has received FDA Fast Track status [6] Group 2: Long COVID Insights - Long COVID is characterized by persistent symptoms of COVID-19 lasting three months or more, affecting over 17 million adults in the U.S., with a potential prevalence of up to 22% [5] - The economic impact of long COVID is estimated at $3.7 trillion, highlighting the significant loss in quality of life and increased medical costs [5] - Currently, there are no proven effective therapies for the treatment of long COVID, indicating a substantial unmet medical need [5] Group 3: Research and Development - The ADDRESS-LC trial is evaluating bezisterim for long COVID, with a focus on chronic neuroinflammation potentially driven by the viral spike protein [2] - The event will include a live Q&A session to engage with participants and address inquiries regarding the trial and treatment options [3]
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025